Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-9 of 9 for your search:
Drug:
milodistim
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of PIXY321 vs GM-CSF for Mobilization of Hematopoietic Progenitors in Women with Metastatic Breast Carcinoma (Summary Last Modified 03/97)
Phase:
Phase III
Type:
Treatment
Status:
Completed
Age:
no greater than 60
Sponsor:
NCI
Protocol IDs:
NU-93B1
, NCI-T93-0058D, T93-0058
2.
Phase III Randomized Study of PIXY321 Both Before and After vs Only After ICE (IFF/CBDCA/VP-16) to Ameliorate Myelotoxicity in Patients with Previously Untreated Malignancies (Summary Last Modified 03/96)
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
over 18
Sponsor:
Other
Protocol IDs:
YALE-HIC-7653
, NCI-V94-0553
3.
Phase III Randomized Pilot Study of GM-CSF Alone vs G-CSF Alone vs GM-CSF/G-CSF vs PIXY321 for Mobilization of PBSC in Cancer Patients Undergoing Autologous Bone Marrow Transplantation (Summary Last Modified 10/94)
Phase:
Phase III
Type:
Treatment
Status:
Completed
Age:
over 18 to under 65
Sponsor:
NCI
Protocol IDs:
URCC-6492H
, NCI-T92-0010D, T92-0010
4.
Phase III Randomized Study of GM-CSF vs PIXY321 in Patients with Advanced Breast Cancer Receiving FLAC (5-FU/CF/DOX/CTX) Followed by 5 Courses of Continuous-Infusion TAX without Growth Factors (Summary Last Modified 05/94)
Phase:
Phase III
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-93-C-0153I
, NCI-MB-318, NCI-T93-0041N, T93-0041
5.
Phase I/II Study of PIXY321 (GM-CSF/IL-3 S. cerevisiae Fusion Protein) in Combination with CTX/CBDCA in Patients with Advanced Epithelial Ovarian Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 to 70
Sponsor:
Protocol IDs:
AECM-9202054
, NCI-V92-0080
6.
Phase II Pilot Study of High-Dose ARA-C/DHAD with PIXY321 as Remission Induction Therapy for Relapsed/Refractory or Secondary AML, Untreated Poor-Prognosis AML, CML in Myeloid Blast Crisis, and Myelodysplastic Syndromes (Summary Last Modified 03/95)
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 to 69
Sponsor:
NCI
Protocol IDs:
MUSC-T93-0112
, NCI-T93-0112O, T93-0112
7.
Phase II Comparative Study of CBDCA/TAX/PIXY321 with vs without PIXY321 Prechemotherapy Hematopoietic Stimulation for Gynecologic Malignancies (Summary Last Modified 03/97)
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MDA-DM-93083
, NCI-T93-0132D, T93-0132
8.
Phase I Study of IL-3/GM-CSF Fusion Protein (PIXY321) and CBDCA in Patients with Advanced Cancer (Summary Last Modified 03/94)
Phase:
Phase I
Type:
Supportive care, Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
BRMP-9108A
, NCI-92-C-0079A, NCI-T91-0213N, T91-0213
9.
Phase I Study of PIXY321 Following ICE (IFF/CBDCA/VP-16) in Children with Recurrent Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Closed
Age:
1 to 21 at entry
Sponsor:
NCI
Protocol IDs:
CCG-0924
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute